A cytotoxic electronegative LDL subfraction is present in human plasma

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 16, Issue 6, 1996, Pages 773-783

  Demuth, Karine ^a,b,d   Myara, Isaac ^a,b   Chappey, Béatrice ^b   Vedie, Benoit ^a,b   Pech Amsellem, Marie Agnès ^b   Haberland, Margaret E ^a,b,c,d   Moatti, Nicole ^a,b  

^a HÔPITAL BROUSSAIS   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Fac Des Sci Pharmaceutiques et B   (France)

Author keywords

atherosclerotic risk factors; cytotoxicity; electronegativity; human umbilical vein endothelial cell; low density lipoprotein

Indexed keywords

ALKADIENE; ALPHA TOCOPHEROL; APOLIPOPROTEIN A; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; LACTATE DEHYDROGENASE; LIPID; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; NEUTRAL RED; PROTEIN; SIALIC ACID; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

AGAR GEL ELECTROPHORESIS; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CYTOTOXICITY; ENZYME ACTIVITY; FAST PROTEIN LIQUID CHROMATOGRAPHY; FETUS; HUMAN; HUMAN CELL; IMMUNOAFFINITY CHROMATOGRAPHY; ION EXCHANGE CHROMATOGRAPHY; PLASMA; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; RECEPTOR BINDING; RISK FACTOR; ULTRACENTRIFUGATION; VASCULAR ENDOTHELIUM;

EID: 0029940303     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.16.6.773     Document Type: Article

References (60)

1. Steinberg D, Parthasarathy S, Carew TE, Khoo JG, Witztum JL. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med. 1989;320:915-924.
2. Steinbrecher UP, Zhang H, Lougheed M. Role of oxidatively modified LDL in atherosclerosis. Free Radic Biol Med. 1990;9:155-168.
3. Brown MS, Goldstein JL. Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. Annu Rev Biochem. 1983;52:223-261.
4. Avogaro P, Bittolon-Bon G, Cazzolato G. Presence of a modified low density lipoprotein in humans. Arteriosclerosis, 1988;8:79-87.
5. Haberland ME, Fong D, Cheng L. Malondialdehyde-altered protein occurs in atheroma of Watanabe heritable hyperlipidemic rabbits. Science. 1988;241:215-218.
6. Palinski W, Rosenfeld ME, Ylä-Herttuala S, Gurtner GC, Socher SS, Butler SW, Parthasarathy S, Carew TE, Steinberg D, Witztum JL. Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci USA. 1989;86:1372-1376.
7. Ylä-Herttuala S, Palinski W, Rosenfeld ME, Parthasarathy S, Carew TE, Butler S, Witztum JL, Steinberg D. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest. 1989;84:1086-1095.
8. Esterbauer H, Jürgens G, Quehenberger O, Koller E. Autoxidation of human low density lipoprotein: loss of polyunsaturated fatty acids and vitamin E and generation of aldehydes. J Lipid Res. 1987;28:495-509.
9. Frei B, Stocker R, Ames BN. Antioxidant defenses and lipid peroxidation in human blood plasma. Proc Natl Acad Sci USA. 1988;85:9748-9752.
10. Avogaro P, Cazzolato G, Bittolon-Bon G. Some questions concerning a small, more electronegative LDL circulating in human plasma. Atherosclerosis. 1991;91:163-171.
11. Cazzolato G, Avogaro P, Bittolon-Bon G. Characterization of a more electronegatively charged LDL subfraction by ion exchange HPLC. Free Radic Biol Med. 1991;11:247-253.
12. Hodis HN, Kramsch DM, Avogaro P, Bittolon-Bon G, Cazzolato G, Hwang J, Peterson H, Sevanian A. Biochemical and cytotoxic characteristics of an in vivo circulating oxidized low density lipoprotein (LDL-). J Lipid Res. 1994;35:669-677.
13. Leake DS. Oxidized low density lipoproteins and atherogenesis. Br Heart J. 1993;69:476-478.
14. Steinbrecher UP, Parthasarathy S, Leake DS, Witztum JL, Steinberg D. Modifications of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc Natl Acad Sci USA. 1984;81:3883-3887.
15. Shimano H, Yamada N, Ishibashi S, Mokuno H, Mori N, Gotoda T, Harada K, Akanuma Y, Murase T, Yazaki Y, Takaku F. Oxidationlabile subfraction of human plasma low density lipoprotein isolated by ion-exchange chromatography. J Lipid Res. 1991;32:763-773.
16. Vedie B, Myara I, Pech MA, Mazière JC, Caprani A, Moatti N. Fractionation of charge-modified low density lipoproteins by fast protein liquid chromatography. J Lipid Res. 1991;32:1359-1369.
17. Goldstein JL, Ho YK, Basu SK, Brown MS. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci USA. 1979;76:333-337.
18. Henriksen T, Evensen SA, Carlander B. Injury to human endothelial cells in culture induced by low density lipoproteins. Scand J Clin Lab Invest. 1979;39:361-368.
19. Henriksen T, Mahoney EM, Steinberg D. Enhanced macrophage degradation of low density lipoprotein previously incubated with cultured endothelial cells: recognition by receptors for acetylated low density lipoprotein. Proc Natl Acad Sci USA. 1981;78:6499-6503.
20. Hessler JR, Morel DW, Lewis J, Chisolm GM. Lipoprotein oxidation and lipoprotein-induced cytotoxicity. Arteriosclerosis. 1983;3:215-222.
21. Fogelman AM, Schechter I, Seager J, Hokom M, Childs JS, Edwards PA. Malondialdehyde alteration of low density lipoproteins leads to cholesterol ester accumulation in human monocyte-derived macrophages. Proc Natl Acad Sci USA. 1980;77:2214-2218.
22. Noble RP. Electrophoretic separation of plasma lipoproteins in agarose gel. J Lipid Res. 1968;9:693-700.
23. Warren L. The thiobarbituric assay of sialic acids. J Biol Chem. 1959;234:1971-1975.
24. Yagi KA. A simple fluorimetric assay for lipoperoxide in blood plasma. Biochem Res. 1976;15:212-216.
25. McFarlane AS. Efficient trace-labelling of proteins with iodine. Nature. 1958;182:53-56.
26. Bilheimer DW, Eisenberg S, Levy RI. The metabolism of very low density lipoproteins, I: preliminary in vitro and in vivo observations. Biochim Biophys Acta. 1972;260:212-221.
27. Goldstein JL, Brown MS. Binding and degradation of low density lipoproteins by cultured human fibroblasts. j Biol Chem. 1974;249:5153-5162.
28. Chappey B, Myara I, Giral P, Kerharo G, Plainfosse MC, Levenson J, Simon A, Moatti N, and the PCVMETRA Group. Evaluation of the sialic acid content of LDL as a marker of coronary calcification and extracoronary atherosclerosis in asymptomatic hypercholesterolemic subjects. Arterioscler Thromb Vasc Biol. 1995;15:334-339.
29. Peterson GL. A simplification of the protein assay method of Lowry et al which is more generally applicable. Anal Biochem. 1977;83:346-356.
30. Horio T, Kohno M, Yasunari K, Murakawa K, Yokokawa K, Ikeda M, Fukui T, Takeda T. Stimulation of endothelin-1 release by low density and very low density lipoproteins in cultured human endothelial cells. Atherosclerosis. 1993;101:185-190.
31. Triau JE, Meydani SN, Schaefer EJ. Oxidized low density lipoprotein stimulates prostacyclin production by adult human vascular endothelial cells. Arteriosclerosis. 1988;8:810-818.
32. Shen MS, Krauss RM, Lindgren FT, Forte TM. Heterogeneity of serum low density lipoproteins in normal human subjects. J Lipid Res. 1981;22:236-244.
33. Nelson CA, Morris MD. The ultracentrifugal heterogeneity of serum low density lipoproteins in normal humans. Biochem Med. 1977;18:1-9.
34. Kirchhausen TG, Fless G, Scanu AM. The structure of plasma low density lipoproteins: experimental facts and interpretation - a minireview. Lipids. 1980;15:464-467.
35. Sundaram SG, Shakir KMM, Margolis S. Preparative isoelectric focusing of human serum very low-density and low-density lipoproteins. Anal Biochem. 1978;88:425-433.
36. Rudel LL, Parks JS, Johnson FL, Babiak J. Low density lipoproteins in atherosclerosis. J Lipid Res. 1986;27:465-474.
37. Krauss RM. Heterogeneity of plasma low density lipoproteins and atherosclerosis risk. Curr Opin Lipidol. 1994;5:339-349.
38. Esterbauer H, Dieber-Rotheneder M, Waeg G, Striegl G, Jürgens G. Biochemical, structural, and functional properties of oxidized low-density lipoprotein. Chem Res Toxicol. 1990;3:77-92.
39. Esterbauer H, Gebicki J, Puhl H, Jürgens G. The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Radic Biol Med. 1992;13:341-390.
40. Ito Y, Breslow JL, Chait BT. Apolipoprotein C-IIIo lacks carbohydrate residues: use of mass spectrometry to study apolipoprotein structure. J Lipid Res. 1989;30:1781-1787.
41. Mahley RW, Innerarity TL, Rall SC Jr, Weisgraber KH. Plasma lipoproteins: apolipoprotein structure and function. J Lipid Res. 1984;25:1277-1294.
42. Remaley AT, Wong AW, Schumacher UK, Meng MS, Brewer HB Jr, Hoeg JM. O-linked glycosylation modifies the association of apolipoprotein A-II to high density lipoproteins. J Biol Chem. 1993;268:6785-6790.
43. Agnani G, Bard JM, Candelier L, Delattre S, Fruchart JC, Clavey V. Interaction of LpB, LpB:E, LpB:C-III, and LpB:C-III:E lipoproteins with the low density lipoprotein receptor of HeLa cells. Arteriosder Thromb. 1991;11:1021-1029.
44. Clavey V, Agnani G, Bard JM, Lestavel-Delattre S, Fruchart JC. Interaction entre le LDL-récepteur et les lipoprotéines contenant de l'apo B. Ann Endocrinol (Paris). 1991;52:459-463.
45. Chapman MJ, Cadman H, Laplaud PM. Heterogeneity in apo-B,E receptor binding of human LDL subspecies. Circulation. 1984;70(suppl II):II-137. Abstract.
46. Gabelli C, Gregg RE, Zech LA, Manzato E, Brewer HB. Abnormal low density lipoprotein metabolism in apolipoprotein E deficiency. J Lipid Res. 1986;27:326-333.
47. Flavahan NA. Atherosclerosis or lipoprotein-induced endothelial dysfunction: potential mechanisms underlying reduction in EDRF/nitric oxide activity. Circulation. 1992;85:1927-1938.
48. Dicorleto PE, Soyombo AA. The role of endothelium in atherogenesis. Curr Opin Lipidol. 1993;4:364-372.
49. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-809.
50. Bruckdorfer KR. Nonenzymatic oxidation of lipids and lipoproteins: the role of metals and nitric oxide. Curr Opin Lipidol. 1993;4:238-243.
51. Pech MA, Myara I, Moatti N. Influence of culture medium characteristics on the ability to oxidize low-density lipoproteins. Bioelectrochem Bioenerg. 1993;29:277-288.
52. Sparrow CP, Olszewski J. Cellular oxidation of low density lipoproteins is caused by thiol production in media containing transition metal ions. J Lipid Res. 1993;34:1219-1228.
53. Morel DW, Hessler JR, Chisolm GM. Low density lipoprotein cytotoxicity induced by free radical peroxidation of lipid. J Lipid Res. 1983;24:1070-1076.
54. Pettersen KS, Boberg KM, Stabursvik A, Prydz H. Toxicity of oxygenated cholesterol derivatives toward cultured human umbilical vein endothelial cells. Arterioscler Thromb. 1991;11:423-428.
55. Dousset N, Dousset JC, Taus M, Ferretti G, Curatola G, Soléra ML, Valdiguié P. Effect of desialylation on low density lipoproteins: comparative study before and after oxidative stress. Biochem Mol Biol Int. 1994;32:555-563.
56. Myara I, Haberland ME, Demuth K, Chappey B, Moatti N. Susceptibility to copper oxidation of neuraminidase-treated LDL. Clin Chim Acta. 1995;240:221-223.
57. Holvoet P, Perez G, Zhao Z, Brouwers E, Bernar H, Collen D. Malondialdehyde-modified low density lipoproteins in patients with atherosclerotic disease. J Clin Invest. 1995;95:2611-2619.
58. Sevanian A, Hodis HN, Hwang J, McLeod LL, Peterson H. Characterization of endothelial cell injury by cholesterol oxidation products found in oxidized LDL. J Lipid Res. 1995;36:1971-1986.
59. Ji ZS, Brecht WJ, Miranda RD, Hussain MM, Innerarity TL, Mahley RW. Role of heparan sulfate proteoglycans in the binding and uptake of apolipoprotein E-enriched remnant lipoproteins by cultured cells. J Biol Chem. 1993;268:10160-10167.
60. Parks JS, Gebre AK, Edwards IJ, Wagner WD. Role of LDL subfraction heterogeneity in the reduced binding of low density lipoproteins to arterial proteoglycans in cynomolgus monkeys fed a fish oil diet. J Lipid Res. 1991;32:2001-2008.